There is a critical unmet need for predictors of chemo-refractory High-grade serous ovarian cancer (HGSOC). Despite over 3 decades of research on platinum responses in cancer, no predictive biomarker has been translated into clinical use. Predictors of refractory disease could spare these patients the unnecessary toxicity of a platinum-based regimen and provide a means to triage these patients to clinical trials to identify effective therapies for refractory disease. This study has approached the development of a predictor in a novel way enabling detection of a multi-analyte panel biomarker capable of detecting a subset of refractory HGSOCs with high specificity and implicating potential treatment vulnerabilities for refractory disease. We reported the first proteogenomic analysis of platinum refractoriness in HGSOC and made the novel dataset available as a resource to the community, including a ProTrack portal: <a href="http://ptrc.cptac-data-view.org/">http://ptrc.cptac-data-view.org/</a>. Detailed proteogenomic profiles were generated for this study from a retrospective cohort of 242 treatment-naive HGSOCs with enriched representation of "exceptional non-responders" (i.e., patients with chemo-refractory disease). Whole genome sequence (WGS) and RNA seq FASTQ files are available through <a href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login">dbGaP</a>. Proteomic data are available through the NCI Proteomic Data Commons (PDC): <a href="https://pdc.cancer.gov/pdc/">https://pdc.cancer.gov/pdc/</a>.

CPTAC: Proteogenomic Studies of Ovarian Tumor Responses to Agents    Targeting the DNA Damage Response

Carcinoma, Ovarian Epithelial study with RNA-Seq, WGS data on dbGaP (148 participants)

CPTAC: Proteogenomic Studies of Ovarian Tumor Responses to Agents Targeting the DNA Damage Response

Description

Applying For Access

Summary